Study S000583

TREAT-EC (Tirzepatide in the Treatment of Endometrial Cancer) A Phase II Pilot Clinical Trial.

Name: LivingGLP1 adjudicated trial data and network meta-analysis results
Creator: Ahmad Sofi-Mahmudi
License: https://creativecommons.org/licenses/by/4.0/

ClinicalTrials.gov record

Registration

Registration: NCT07605247
Acronym: TREAT-EC
Study type: INTERVENTIONAL
Phase: PHASE2
Masking: NONE
Status: NOT_YET_RECRUITING
Enrollment: 30
Start: 2026-06-01
Primary completion: 2028-01
Lead sponsor: Rutgers, The State University of New Jersey
Conditions: Endometrial Cancer
Interventions: DRUG:Tirzepatide; DEVICE:LNG-IUD plus tirzepatide
Results posted: FALSE

Registered primary outcomes

Quality of Life Quality of life will be measured through PROMs at the time points listed below for explorative purposes. [● Screening (day -30 to Week 0) ● 3 months (Visit 4, Week 12) ● 6 months (Visit 7, Week 24) ● 9 months (Visit 10, Week 36)]

Linked records (0)

Automatic links, confirmed or rejected during screening. A record citing this registration may be a secondary analysis, a commentary or a review that mentions the trial.

No records link to this registration yet.